Alnylam Pharmaceuticals (ALNY) Competitors $314.94 -7.70 (-2.39%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$314.32 -0.63 (-0.20%) As of 07/11/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY vs. AMGN, GILD, VRTX, REGN, BIIB, UTHR, INCY, NBIX, EXEL, and BMRNShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Its Competitors Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Amgen (NASDAQ:AMGN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation. Does the media favor AMGN or ALNY? In the previous week, Amgen had 30 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 50 mentions for Amgen and 20 mentions for Alnylam Pharmaceuticals. Amgen's average media sentiment score of 1.52 beat Alnylam Pharmaceuticals' score of 1.14 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 45 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, AMGN or ALNY? Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Do institutionals and insiders believe in AMGN or ALNY? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.8% of Amgen shares are owned by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher earnings and valuation, AMGN or ALNY? Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$34.13B4.65$4.09B$10.9626.94Alnylam Pharmaceuticals$2.35B17.49-$278.16M-$2.09-150.69 Do analysts rate AMGN or ALNY? Amgen presently has a consensus target price of $307.82, indicating a potential upside of 4.25%. Alnylam Pharmaceuticals has a consensus target price of $345.70, indicating a potential upside of 9.77%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 12 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.35Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is AMGN or ALNY more profitable? Amgen has a net margin of 17.39% compared to Alnylam Pharmaceuticals' net margin of -11.49%. Amgen's return on equity of 176.11% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amgen17.39% 176.11% 12.39% Alnylam Pharmaceuticals -11.49%-510.31%-6.48% SummaryAmgen beats Alnylam Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.06B$2.96B$5.61B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-150.6920.8528.1820.27Price / Sales17.49289.80428.6998.03Price / CashN/A42.8637.4658.16Price / Book605.657.638.045.49Net Income-$278.16M-$55.05M$3.19B$250.45M7 Day Performance-5.12%8.43%3.62%4.79%1 Month Performance3.37%5.42%4.06%7.68%1 Year Performance20.89%2.03%30.00%16.43% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals4.1806 of 5 stars$314.94-2.4%$345.70+9.8%+20.7%$41.06B$2.35B-150.692,230Positive NewsAnalyst ForecastAMGNAmgen4.4341 of 5 stars$292.95-1.8%$307.82+5.1%-9.2%$157.52B$33.42B26.7328,000Positive NewsAnalyst RevisionGILDGilead Sciences4.9342 of 5 stars$111.78+0.0%$110.55-1.1%+56.7%$139.05B$28.75B23.5317,600Positive NewsAnalyst RevisionVRTXVertex Pharmaceuticals4.3242 of 5 stars$459.410.0%$511.62+11.4%-4.7%$117.98B$11.10B-117.206,100Positive NewsAnalyst RevisionREGNRegeneron Pharmaceuticals4.8318 of 5 stars$538.11-1.7%$813.57+51.2%-47.4%$58.09B$14.20B13.7015,106Trending NewsAnalyst ForecastAnalyst RevisionBIIBBiogen4.7787 of 5 stars$130.13-2.1%$188.48+44.8%-43.3%$19.07B$9.68B12.857,605Trending NewsAnalyst RevisionUTHRUnited Therapeutics4.9895 of 5 stars$290.39-1.4%$386.15+33.0%-8.8%$13.10B$2.88B11.591,305Analyst ForecastINCYIncyte4.7302 of 5 stars$67.27-1.7%$74.53+10.8%+10.1%$13.02B$4.24B210.232,617NBIXNeurocrine Biosciences4.4743 of 5 stars$127.88-1.0%$162.00+26.7%-8.9%$12.66B$2.36B43.351,800Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionEXELExelixis4.79 of 5 stars$44.16-4.3%$43.56-1.4%+98.9%$12.04B$2.17B20.071,147Analyst ForecastBMRNBioMarin Pharmaceutical4.9484 of 5 stars$57.41-0.2%$93.61+63.1%-30.8%$11.01B$2.85B21.343,040News CoveragePositive News Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNY) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts